Fundsmith Reduces $195M in Stryker Corporation ($SYK)

Key Points

  • Fundsmith changed its Stryker Corporation ($SYK) stake by 17.0% last quarter, cutting to 3,061,416 shares worth $955.77 million.
  • Wall Street's consensus rating on $SYK is Buy and an average price target of $386.80.
  • $SYK last traded around $312.20.

Fundsmith reduced its position in Stryker Corporation ($SYK) by 17.0% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,061,416 shares of Stryker Corporation after selling 626,095 shares during the quarter. Fundsmith's holdings in Stryker Corporation were worth $955.77 million as of its most recent filing.

Stryker Corporation ($SYK) Stock

Last price$312.20
Market cap$119.69B
P/E ratio36.09
Forward P/E18.67
PEG ratio1.49
Beta0.79
52-week low$281.00
52-week high$404.87
50-day MA$315.17
200-day MA$352.36
Current ratio2.11
Quick ratio1.03
Debt-to-equity0.66

Stryker Corporation Earnings

EPS (ttm)$8.65
Revenue (ttm)$25.27B
Revenue growth2.6%
Net margin13.2%
Return on equity15.2%
Next earningsJul 30, 2026

Stryker Corporation Dividend

Annual dividend$3.52
Dividend yield113.00%
Payout ratio39.8%
Ex-dividend dateJun 30, 2026

Analysts Set New Price Targets

ConsensusBuy
Average target$386.80
High target$465.00
Low target$315.00
Analysts covering25

About Stryker Corporation

Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

ExchangeNYSE
SectorHealthcare
IndustryMedical Devices
HeadquartersPortage, MI
CEOMr. Kevin A. Lobo
Employees56,000

See Also

This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.